1. Home
  2. ANAB vs BHRB Comparison

ANAB vs BHRB Comparison

Compare ANAB & BHRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ANAB
  • BHRB
  • Stock Information
  • Founded
  • ANAB 2005
  • BHRB 1852
  • Country
  • ANAB United States
  • BHRB United States
  • Employees
  • ANAB N/A
  • BHRB N/A
  • Industry
  • ANAB Biotechnology: Pharmaceutical Preparations
  • BHRB Major Banks
  • Sector
  • ANAB Health Care
  • BHRB Finance
  • Exchange
  • ANAB Nasdaq
  • BHRB Nasdaq
  • Market Cap
  • ANAB 759.5M
  • BHRB 865.8M
  • IPO Year
  • ANAB 2017
  • BHRB N/A
  • Fundamental
  • Price
  • ANAB $19.59
  • BHRB $56.71
  • Analyst Decision
  • ANAB Buy
  • BHRB Strong Buy
  • Analyst Count
  • ANAB 10
  • BHRB 2
  • Target Price
  • ANAB $37.75
  • BHRB $73.00
  • AVG Volume (30 Days)
  • ANAB 589.1K
  • BHRB 33.8K
  • Earning Date
  • ANAB 05-05-2025
  • BHRB 04-25-2025
  • Dividend Yield
  • ANAB N/A
  • BHRB 3.89%
  • EPS Growth
  • ANAB N/A
  • BHRB 46.75
  • EPS
  • ANAB N/A
  • BHRB 3.98
  • Revenue
  • ANAB $111,872,000.00
  • BHRB $288,482,000.00
  • Revenue This Year
  • ANAB N/A
  • BHRB $51.18
  • Revenue Next Year
  • ANAB $44.69
  • BHRB $4.49
  • P/E Ratio
  • ANAB N/A
  • BHRB $14.21
  • Revenue Growth
  • ANAB 387.20
  • BHRB 168.31
  • 52 Week Low
  • ANAB $12.21
  • BHRB $46.00
  • 52 Week High
  • ANAB $41.31
  • BHRB $75.32
  • Technical
  • Relative Strength Index (RSI)
  • ANAB 48.98
  • BHRB 58.96
  • Support Level
  • ANAB $18.51
  • BHRB $55.63
  • Resistance Level
  • ANAB $21.52
  • BHRB $58.00
  • Average True Range (ATR)
  • ANAB 1.16
  • BHRB 1.81
  • MACD
  • ANAB -0.26
  • BHRB 0.72
  • Stochastic Oscillator
  • ANAB 26.97
  • BHRB 84.73

About ANAB AnaptysBio Inc.

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

About BHRB Burke & Herbert Financial Services Corp.

Burke & Herbert Financial Services Corp is the bank holding company. Through its subsidiary, it predominantly serves small to medium-sized businesses, their owners and employees, professional corporations, non-profits, and individuals with various banking products and financial services. Some of its products and service offerings include checking, savings, and money market accounts, certificates of deposit, treasury and cash management services, commercial and industrial loans, commercial real estate loans, residential mortgage, acquisition, construction, and development loans, online banking, mobile banking, and wealth and trust services. The company operates in a single segment, namely Community Banking.

Share on Social Networks: